

Tracy Ann Williams

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3539095/tracy-ann-williams-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68

papers

3,720

citations

32

h-index

60

g-index

72

ext. papers

4,483

ext. citations

6

avg, IF

5.08

L-index

#	Paper	IF	Citations
68	Development of a Prediction Score to Avoid Confirmatory Testing in Patients With Suspected Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e1708-e1716	5.6	4
67	Pathophysiology and histopathology of primary aldosteronism. <i>Trends in Endocrinology and Metabolism</i> , 2021 ,	8.8	3
66	International Histopathology Consensus for Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 42-54	5.6	42
65	Single-Center Prospective Cohort Study on the Histopathology, Genotype, and Postsurgical Outcomes of Patients With Primary Aldosteronism. <i>Hypertension</i> , 2021 , 78, 738-746	8.5	9
64	The saline infusion test for primary aldosteronism: implications of immunoassay inaccuracy.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	5
63	Development and Validation of Prediction Models for Subtype Diagnosis of Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	18
62	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	11
61	Diverse Responses of Autoantibodies to the Angiotensin II Type 1 Receptor in Primary Aldosteronism. <i>Hypertension</i> , 2019 , 74, 784-792	8.5	13
60	Primary Aldosteronism: KCNJ5 Mutations and Adrenocortical Cell Growth. <i>Hypertension</i> , 2019 , 74, 809-816	8.5	18
59	Assessing outcomes after adrenalectomy for unilateral primary aldosteronism. <i>Surgery</i> , 2019 , 166, 1199-1200	3.00	3
58	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019 , 189, 274-282	5.1	22
57	MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. <i>European Journal of Endocrinology</i> , 2018 , 179, R19-R29	6.5	57
56	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2018 , 71, 317-325	8.5	46
55	DIAGNOSIS OF ENDOCRINE DISEASE: 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?. <i>European Journal of Endocrinology</i> , 2018 , 178, R1-R9	6.5	28
54	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018 , 72, 650-657	8.5	36
53	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018 , 72, 641-649	8.5	54
52	Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 41-50	18.1	324

51	Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status. <i>Clinica Chimica Acta</i> , 2017 , 470, 115-124	6.2	70
50	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 689-699	18.1	355
49	Old and New Concepts in the Molecular Pathogenesis of Primary Aldosteronism. <i>Hypertension</i> , 2017 , 70, 875-881	8.5	26
48	Familial hyperaldosteronism type III. <i>Journal of Human Hypertension</i> , 2017 , 31, 776-781	2.6	28
47	Disordered CYP11B2 Expression in Primary Aldosteronism. <i>Hormone and Metabolic Research</i> , 2017 , 49, 957-962	3.1	27
46	Is Primary Aldosteronism Still Largely Unrecognized?. <i>Hormone and Metabolic Research</i> , 2017 , 49, 908-914	4.1	30
45	Mass Spectrometry-Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism. <i>Clinical Chemistry</i> , 2016 , 62, 514-24	5.5	97
44	Genotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas. <i>Hypertension</i> , 2016 , 67, 139-45	8.5	100
43	ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions. <i>Journal of Human Hypertension</i> , 2016 , 30, 374-8	2.6	31
42	Recent Developments in Primary Aldosteronism. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2016 , 124, 335-41	2.3	9
41	Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. <i>Molecular and Cellular Endocrinology</i> , 2015 , 411, 146-54	4.4	96
40	Renin and aldosterone measurements in the management of arterial hypertension. <i>Hormone and Metabolic Research</i> , 2015 , 47, 418-26	3.1	19
39	Understanding primary aldosteronism: impact of next generation sequencing and expression profiling. <i>Molecular and Cellular Endocrinology</i> , 2015 , 399, 311-20	4.4	40
38	Genetic and potential autoimmune triggers of primary aldosteronism. <i>Hypertension</i> , 2015 , 66, 248-53	8.5	7
37	Subtype Diagnosis of Primary Aldosteronism: Approach to Different Clinical Scenarios. <i>Hormone and Metabolic Research</i> , 2015 , 47, 959-66	3.1	6
36	KCNJ5 Mutations: Sex, Salt and Selection. <i>Hormone and Metabolic Research</i> , 2015 , 47, 953-8	3.1	14
35	Steroid Hormone Production in Patients with Aldosterone Producing Adenomas. <i>Hormone and Metabolic Research</i> , 2015 , 47, 967-72	3.1	11
34	A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge Kir3.4 residue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, E114-8	5.6	44

33	Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. <i>Hypertension</i> , 2014 , 63, 188-95	8.5	126
32	1 α ,25-Dihydroxyvitamin D α inhibits the human H295R cell proliferation by cell cycle arrest: a model for a protective role of vitamin D receptor against adrenocortical cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014 , 140, 26-33	5.1	19
31	Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. <i>Hypertension</i> , 2014 , 64, 354-61	8.5	211
30	Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study. <i>Pharmacogenomics</i> , 2014 , 15, 1643-52	2.6	24
29	a Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1861-5	5.6	65
28	Role of KCNJ5 in familial and sporadic primary aldosteronism. <i>Nature Reviews Endocrinology</i> , 2013 , 9, 104-12	15.2	86
27	Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. <i>Molecular and Cellular Endocrinology</i> , 2012 , 355, 162-8	4.4	14
26	Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. <i>Hypertension</i> , 2012 , 59, 592-8	8.5	206
25	Aldosterone does not modify gene expression in human endothelial cells. <i>Hormone and Metabolic Research</i> , 2012 , 44, 234-8	3.1	7
24	KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. <i>Hypertension</i> , 2012 , 59, 235-40	8.5	145
23	Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calcium-induced apoptosis. <i>Hypertension</i> , 2012 , 59, 833-9	8.5	51
22	Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E1567-72	5.6	112
21	Is familial hyperaldosteronism underdiagnosed in hypertensive children?. <i>Hypertension</i> , 2011 , 57, 1053-58.5		14
20	Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TORino-GENetic forms). <i>Hypertension</i> , 2011 , 58, 797-803	8.5	95
19	Teratocarcinoma-derived growth factor-1 is upregulated in aldosterone-producing adenomas and increases aldosterone secretion and inhibits apoptosis in vitro. <i>Hypertension</i> , 2010 , 55, 1468-75	8.5	39
18	LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms. <i>Atherosclerosis</i> , 2009 , 207, 38-44	3.1	52
17	Primary aldosteronism (PA) and endothelial progenitor cell (EPC) bioavailability. <i>Clinical Endocrinology</i> , 2008 , 69, 528-34	3.4	9
16	Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. <i>Kidney International</i> , 2005 , 67, 631-7	9.9	29

15	Bradykinin B2 receptor gene C-58T polymorphism and insulin resistance. A study on obese patients. <i>Hormone and Metabolic Research</i> , 2004 , 36, 243-6	3.1	9
14	A particular phenotype in a girl with aldosterone synthase deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3168-72	5.6	7
13	Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. <i>Journal of Human Hypertension</i> , 2004 , 18, 47-51	2.6	42
12	Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation italian pedigree. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3187-91	5.6	57
11	Blood Pressure in Patients with Primary Aldosteronism Is Influenced by Bradykinin B2 Receptor and β -Adducin Gene Polymorphisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3337-3343	5.6	26
10	Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. <i>Oncogene</i> , 2000 , 19, 1509-18	9.2	145
9	A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. <i>Journal of Biological Chemistry</i> , 1999 , 274, 29274-81	5.4	50
8	MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential. <i>Journal of Cellular Physiology</i> , 1999 , 181, 507-14	7	22
7	Toward a role for angiotensin-converting enzyme in insects. <i>Annals of the New York Academy of Sciences</i> , 1998 , 839, 288-92	6.5	19
6	The <i>Drosophila melanogaster</i> -related angiotensin-I-converting enzymes Acer and Ace--distinct enzymic characteristics and alternative expression during pupal development. <i>FEBS Journal</i> , 1998 , 257, 599-606		68
5	Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. <i>Molecular Pharmacology</i> , 1997 , 51, 1070-6	4.3	60
4	A study of chimeras constructed with the two domains of angiotensin I-converting enzyme. <i>Biochemical Pharmacology</i> , 1996 , 51, 11-4	6	17
3	Cloning and expression of an evolutionary conserved single-domain angiotensin converting enzyme from <i>Drosophila melanogaster</i> . <i>Journal of Biological Chemistry</i> , 1995 , 270, 13613-9	5.4	115
2	A genetic study of angiotensin I-converting enzyme levels in human semen. <i>Molecular and Cellular Endocrinology</i> , 1995 , 107, 215-9	4.4	14
1	Characterization of neuronal and endothelial forms of angiotensin converting enzyme in pig brain. <i>Journal of Neurochemistry</i> , 1991 , 57, 193-9	6	34